Melanotan-II

Safety profile — read this first

Evidence tier: 3 — Multiple peer-reviewed human case reports of serious adverse events from unregulated subcutaneous use; consistent signal across rhabdomyolysis, priapism, renal infarction, and melanocytic lesion change.

We lead with safety because Melanotan-II is the peptide in this directory with the worst documented adverse-event profile relative to its claimed cosmetic benefit. This is a research-context entry, not a how-to-use page.

Documented adverse events in the published case-report literature include:

• Rhabdomyolysis with severe CPK elevation. Nelson 2012 (PMID 23121206) describes a 39-year-old male who self-injected 6 mg subcutaneously and developed CPK rising from 1,760 to 17,773 IU/L over 12 hours, with creatinine 2.25 mg/dL and a 3-day ICU stay. The dose was six times the most common community starting dose; community dosing tolerance is not safety.
• Renal infarction. Reviewed in Devine 2020 (PMID 31953620), where vasoconstrictive effects of α-MSH analogues are implicated in acute renal infarcts in otherwise-healthy users.
• Priapism requiring emergency intervention. Multiple reports including Hilliard 2013 (PMID 23537392) — the same MC4-receptor activity behind PT-141's on-label use becomes a serious adverse event at Melanotan-II doses.
• Melanocytic-lesion change and melanoma case reports. Cardones 2009 documented α-MSH-induced eruptive nevi. Paurobally 2011 (PMID 23052015) showed dermoscopic changes during use that made nevus-vs-melanoma differentiation difficult. Cousen 2014 (PMID 24355990) reports melanoma associated with Melanotan-II use. The mechanistic concern — synthetic α-MSH agonists driving proliferation of neoplastic melanocytes in predisposed patients — is taken seriously by dermatology.

Additional reports describe systemic toxicity with tachycardia, mydriasis, diaphoresis, and tremor (sympathomimetic-like presentations) at supratherapeutic doses. Research-supplier supply also carries the standard contamination and purity risks of unregulated peptide sourcing.

Mechanism

Evidence tier: 4 — Receptor pharmacology well-characterized in preclinical work; in-vivo behavioral and dermatologic effects extrapolated from animal data.

Melanotan-II is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It binds non-selectively to melanocortin receptors 1, 3, 4, and 5. MC1R activation on dermal melanocytes upregulates eumelanin synthesis, producing the skin pigmentation effect that drives the cosmetic interest. MC4R activation in the central nervous system mediates erectile-function and appetite effects (the same receptor PT-141 targets selectively). MC3R and MC5R activity contribute to cardiovascular and exocrine effects that likely underpin some of the off-target adverse events (vasoconstriction, sebaceous changes). Because it is non-selective across the MC receptor family, the off-target activity is intrinsic to the molecule rather than a dose-related artifact — even at "low" cosmetic doses, MC4 and MC3 activation occurs alongside the intended MC1 effect.

Typical protocols

Evidence tier: 5 — All community-evolved; no validated protocol exists. Documenting only to contextualize what's circulating, not to recommend.

There is no clinically validated dosing schema for Melanotan-II. Community-circulated protocols typically describe loading at 0.1-0.5 mg/day subcutaneously for 1-2 weeks, followed by maintenance dosing 2-3 times weekly. These ranges are anecdotal and were derived through forum self-experimentation in the 2000s-2010s, not from clinical trials. The Nelson 2012 case demonstrates how poorly the dose-response curve is mapped — six times a typical starting dose produced life-threatening rhabdomyolysis in a healthy adult. Patients considering this molecule should treat any community-published dosing schedule as unverified.

Evidence by indication

Evidence tier: 4 — Phase 1 trials of related analogs (afamelanotide) exist for narrow indications; Melanotan-II itself has no completed Phase 3 trial in any cosmetic indication.

The original parent program for the melanotan series at the University of Arizona pursued photoprotection in patients with erythropoietic protoporphyria. That program evolved into afamelanotide (Scenesse), a related α-MSH analog that is FDA-approved for EPP. Melanotan-II was abandoned as a clinical candidate. The cosmetic tanning use case has never been validated in a registration trial. There is no completed human RCT supporting Melanotan-II for cosmetic pigmentation, erectile dysfunction, or appetite suppression — despite ad hoc community use across all three indications. The closest validated alternative is afamelanotide for EPP (Phase 3 complete, FDA-approved) and PT-141 / bremelanotide for hypoactive sexual desire disorder in premenopausal women (FDA-approved 2019).

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning; the alternatives have meaningfully better safety + regulatory profiles for every Melanotan-II claimed use case.

For each claimed indication, an FDA-approved or better-evidenced alternative exists:

• Cosmetic tanning — There is no safe pharmacologic alternative, and the documented melanocytic-lesion and melanoma risks make this use case unsupportable. Sun-protection plus DHA-based self-tanners is the only defensible cosmetic path.
• Sexual dysfunction — PT-141 / bremelanotide is the selective MC4 agonist that retains the relevant pharmacology without the MC1/MC3/MC5 off-target activity. FDA-approved with a documented safety profile.
• Appetite suppression — Semaglutide, tirzepatide, and the emerging retatrutide class have RCT-grade weight-loss data without the cardiovascular and dermatologic risk.
• EPP / photoprotection — Afamelanotide (Scenesse) is the FDA-approved option in this narrow indication.

There is no clinical scenario where Melanotan-II is the preferred molecule in 2026.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content describing the access pathway picture.

Melanotan-II is not FDA-approved for any indication, not on the FDA bulks list for 503A or 503B compounding, and is not lawfully available through US compounding pharmacy channels. The UK MHRA and EMA have issued repeated public warnings about unlicensed online sale. WADA does not list Melanotan-II specifically because it is not used in performance contexts. Material circulating in research-supplier channels carries the standard purity, contamination, and dose-accuracy concerns of unregulated peptide sourcing — see our 503A vs 503B framework for why this matters.

Patients who have already used Melanotan-II and have developed pigmented lesions should have full-body dermatologic screening, particularly anyone with a personal or family melanoma history. Discuss any new or changing nevus with a dermatologist.

References

• Nelson ME, Bryant SM, Aks SE. 2012. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). PMID 23121206
• Devine T, Lipgar D, Karp J. 2020. Melanotan II: a possible cause of renal infarction: review of the literature and case report. J Community Hosp Intern Med Perspect. PMID 31953620
• Hilliard L, Klemmer P. 2013. Melanotan II overdose associated with priapism. Clin Toxicol (Phila). PMID 23537392
• Paurobally D, Jason F, Dezfoulian B, Nikkels AF. 2013. Dermoscopic changes in melanocytic nevi during use of melanotan II. Acta Derm Venereol. PMID 23052015
• Cousen P, Colver G, Helbling I. 2014. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. PMID 24355990

Limitations

This page does not constitute medical advice. Patients with existing pigmented lesions, personal or family melanoma history, cardiovascular disease, renal disease, or active sympathomimetic medication use should not consider Melanotan-II under any framing. The case-report literature is not a substitute for the structured pharmacovigilance data we have for FDA-approved alternatives, and the absence of an RCT-grade adverse-event profile means the documented risks are likely an underestimate of the true rate.

We would change our framing only if a registration-quality Phase 3 trial of Melanotan-II were initiated with formal safety monitoring — which would not change our editorial position that the existing alternatives are categorically better choices for every claimed indication.